Cancer’s Vulnerability is Our Strength

Learn More

About Cyteir

Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.

Pipeline

Novel, drug candidates targeting key cancer vulnerabilities

LEARN MORE

Patients

Enrollment is open in our Phase 1/2 trial for advanced ovarian cancer

LEARN MORE